AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PCVX · NASDAQ · Biotechnology

Vaxcyte (PCVX)

Developer of high-valency bacterial vaccine candidates using cell-free protein synthesis.

$56.01

vs last close−3.01 (−5.09%)

California State Teachers Retirement System Has $475.89 Million Stake in Vaxcyte, Inc. $PCVX
Defense WorldSep 15
Vaxcyte Target of Unusually High Options Trading (NASDAQ:PCVX)
Defense WorldSep 9Market move
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing
The Motley FoolSep 8Ownership
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know
The Motley FoolSep 8Ownership
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm
The Motley FoolSep 8Ownership
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
GlobeNewsWireSep 3Leadership
Deutsche Bank AG Makes New $15.02 Million Investment in Vaxcyte, Inc. $PCVX
Defense WorldAug 23Ownership
If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone
24/7 Wall StreetAug 16
Assenagon Asset Management S.A. Decreases Stock Holdings in Vaxcyte, Inc. $PCVX
Defense WorldAug 12
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewsWireAug 5
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of “Hold” from Analysts
Defense WorldAug 4
Bank of New York Mellon Corp Has $27.57 Million Stock Holdings in Vaxcyte, Inc. $PCVX
Defense WorldJul 28
Vaxcyte to Participate in Upcoming Investor Conferences
GlobeNewsWireJul 8
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
GlobeNewsWireJun 2
Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking AlphaMay 12
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
GlobeNewsWireMay 6
Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market
Seeking AlphaMay 1
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
GlobeNewsWireApr 7
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
GlobeNewsWireMar 23
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
GlobeNewsWireMar 18
Bridgefront Capital LLC Increases Stock Holdings in Vaxcyte, Inc. $PCVX
Defense WorldMar 16
Citigroup Inc. Sells 116,206 Shares of Vaxcyte, Inc. $PCVX
Defense WorldMar 1
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Seeking AlphaFeb 24
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
GlobeNewsWireFeb 24